Medicamen Biotech shareholders approve all AGM resolutions
- All eight AGM resolutions passed with 99.999% votes in favor
- 184 shareholders participated via video conferencing
- Promoter group votes excluded for related-party transaction items
- FY26 financial statements and dividend declaration approved
*this image is generated using AI for illustrative purposes only.
Medicamen Biotech Limited concluded its 33rd Annual General Meeting on September 26, 2026, with shareholders approving all eight agenda items. The meeting adopted standalone and consolidated financial statements for FY26 and approved the declaration of a dividend on equity shares.
The meeting was conducted through two-way Video Conferencing and Other Audio-Visual Means, in compliance with SEBI and Ministry of Corporate Affairs circulars. Chairman Rahul Bishnoi presided over the session, which commenced at 12:00 pm and concluded at 12:45 pm. Company Secretary Parul Choudhary managed the proceedings and confirmed the presence of requisite quorum.
Voting results and shareholder participation
Voting results released pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, show near-unanimous support for all resolutions. A total of 184 shareholders participated via Video Conferencing, comprising one from the promoter group and 183 public shareholders. The record date for voting was September 19, 2026, with 12,110 shareholders on record.
For routine business items including the adoption of financial statements, dividend declaration, director reappointments, and auditor remuneration ratification, votes cast in favor accounted for 99.999% of valid votes. Only one vote was recorded against these resolutions.
Key resolutions passed
Shareholders voted on eight agenda items, covering routine business and specific related-party transactions. The resolutions included the adoption of audited financial reports for the year ended March 31, 2026, and the reappointment of key board members.
| Item | Resolution Type | Description | Votes In Favor (%) |
|---|---|---|---|
| 1 | Ordinary | Adopt audited standalone financial statements for FY26 | 99.999% |
| 2 | Ordinary | Adopt audited consolidated financial statements for FY26 | 99.999% |
| 3 | Ordinary | Declare dividend on equity shares | 99.999% |
| 4 | Ordinary | Re-appoint Suresh Kumar Singh as director | 99.999% |
| 5 | Ordinary | Re-appoint Sanjay Bansal as director | 99.999% |
| 6 | Ordinary | Ratify remuneration of cost auditors | 99.999% |
| 7 | Ordinary | Approve material related party transactions with Shivalik Rasayan Limited | 99.999%* |
| 8 | Ordinary | Approve material related party transactions with Medicamen Life Sciences Private Limited | 99.999%* |
Note: For Items 7 and 8, promoter group votes were treated as invalid/abstained due to related-party status. Results reflect public shareholder votes only.
Related-party transaction approvals
Items 7 and 8 involved approvals for material related-party transactions with Shivalik Rasayan Limited, the holding company, and Medicamen Life Sciences Private Limited, a subsidiary. Since the promoter group is interested in these transactions, their votes were excluded from the final tally as invalid or abstained. Among eligible public shareholders, 761,263 votes were cast in favor against just one vote against, resulting in a 99.999% approval rate.
Compliance and scrutinizer report
Remote e-voting was available to members from September 23 to September 25, 2026. M/s AMJ & Associates served as the scrutinizer for the voting process. The consolidated scrutinizer's report confirmed that no qualification or adverse remark existed in the statutory auditor's report. However, the secretarial auditor's report contained certain observations, for which management explanations were provided in the Board's Report. Results were published on the company website and communicated to stock exchanges.
Historical Stock Returns for Medicamen Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.69% | -0.34% | +37.41% | +30.23% | +0.58% | -40.77% |
How will the approved material related-party transactions with Shivalik Rasayan Limited and Medicamen Life Sciences Private Limited impact Medicamen Biotech's future operational independence and cost structure?
What specific observations were noted in the secretarial auditor's report, and how might management's explanations influence regulatory scrutiny in the coming fiscal year?
Given the near-unanimous shareholder support and low public participation (1.5% of record holders), what strategies is the company planning to enhance minority shareholder engagement in future AGMs?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
